GlassScriptPhysician profile
Robert B Nadler
NPI 1982623401
$70,473.74
in general payments reported to CMS, 2019-2025
30 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $16K · 2021: $22K · 2022: $3,653 · 2023: $350 · 2024: $477 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.82 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $66,818.35 | 2019-2022 | |
| Boston Scientific Corporation | $1,078.13 | 2019-2025 | Lithovue, Axonics |
| Procept Biorobotics Corporation | $607.66 | 2024-2025 | Aquabeam System |
| Janssen Biotech, INC. | $241.91 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Coloplast Corp | $215.72 | 2019-2022 | |
| Urogen Pharma, INC. | $213.97 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $203.15 | 2023-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $177.46 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $113.40 | 2022-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $76.28 | 2022-2025 | Imfinzi |
| Olympus America INC. | $75.66 | 2022-2023 | Itind System |
| Pfizer INC. | $61.88 | 2023-2025 | |
| Medtronic, INC. | $61.85 | 2022 | |
| Olympus Corporation of The Americas | $61.16 | 2022 | |
| Abbvie INC. | $57.75 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $50.63 | 2023-2025 | Litho 150, Williams |
| Dendreon Pharmaceuticals LLC | $49.49 | 2025 | Provenge |
| Intuitive Surgical, INC. | $46.46 | 2024 | |
| Myriad Genetic Laboratories, INC. | $38.62 | 2024 | Prolaris |
| Neotract INC. | $30.61 | 2020 | |
| Astellas Pharma US INC | $28.83 | 2022-2023 | Myrbetriq |
| 180 Medical, INC. | $24.64 | 2020 | |
| Ambu INC. | $23.62 | 2024 | |
| Endo USA, INC. | $21.41 | 2025 | Edex, Xiaflex, Aveed |
| Profound Medical Corp. | $19.60 | 2025 | Tulsa-Pro |
| Laborie Medical Technologies Corp. | $18.89 | 2023 | |
| Ethicon US, LLC | $16.08 | 2022 | |
| Abc Home Medical Supply, INC. | $14.41 | 2024 | |
| Progenics Pharmaceuticals, INC. | $13.91 | 2021 | |
| Metuchen Pharmaceuticals | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.